Order Article Reprints

Goyal NA, Andrews JA, Oskarsson BE, Wiedau MH, Kasarskis EJ, Forrest BD, Zhang R, Bracci PM, Davis MW, Azhir A, et al. Quantitative Measures of Time to Loss of 15% Vital Capacity and Survival Extension in Slowly Progressive Amyotrophic Lateral Sclerosis (ALS) Patients Treated with the Immune Regulator NP001 Suggests an Immunopathogenic Subset of ALS. Biomedicines. 2025; 13(12):3060. https://doi.org/10.3390/biomedicines13123060

Goyal, Namita A., Jinsy A. Andrews, Björn E. Oskarsson, Martina H. Wiedau, Edward J. Kasarskis, Bruce D. Forrest, Rongzhen Zhang, Paige M. Bracci, Matthew W. Davis, Ari Azhir, and et al. 2025. "Quantitative Measures of Time to Loss of 15% Vital Capacity and Survival Extension in Slowly Progressive Amyotrophic Lateral Sclerosis (ALS) Patients Treated with the Immune Regulator NP001 Suggests an Immunopathogenic Subset of ALS" Biomedicines 13, no. 12: 3060. https://doi.org/10.3390/biomedicines13123060

Goyal, N. A., Andrews, J. A., Oskarsson, B. E., Wiedau, M. H., Kasarskis, E. J., Forrest, B. D., Zhang, R., Bracci, P. M., Davis, M. W., Azhir, A., & McGrath, M. S. (2025). Quantitative Measures of Time to Loss of 15% Vital Capacity and Survival Extension in Slowly Progressive Amyotrophic Lateral Sclerosis (ALS) Patients Treated with the Immune Regulator NP001 Suggests an Immunopathogenic Subset of ALS. Biomedicines, 13(12), 3060. https://doi.org/10.3390/biomedicines13123060